Neurothrombectomy in acute ischaemic stroke: a prospective single‐centre study and comparison with randomized controlled trials. (5th February 2016)

• Record Type: Journal Article
• Authors: Nikoubashman, O.; Jungbluth, M.; Schürmann, K.; Müller, M.; Falkenburger, B.; Tauber, S. C.; Wiesmann, M.; Schulz, J. B.; Reich, A.
• Is Part Of: European journal of neurology. Volume 23:Number 4(2016:Apr.)
• Page Start: 807
• Page End: 816
• Publication Date: 2016-02-05
• Subjects: acute ischaemic stroke (AIS) -- neurothrombectomy -- randomized controlled trials (RCTs) -- single‐centre and real‐world study; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.12944
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract : Background and purpose: In the last few months five multicentre, randomized controlled trials (RCTs) unequivocally showed the superiority of mechanical thrombectomy in large vessel occlusion acute ischaemic stroke compared to systemic thrombolysis. Despite varying inclusion criteria and time intervals from onset to revascularization overall increases of good functional outcome between 55% and 81% were reported. However, only a minority of screened patients (approximately 1%) were eligible for intra‐arterial (IA) therapy. Methods: An investigator‐initiated, single‐centre, prospective and blinded end‐point analysis was performed of 3123 consecutive patients with acute ischaemic stroke presenting between February 2010 and December 2014. Results: One hundred and fifty‐four patients [4.9%, age (years) mean (SD), median (interquartile range) 71.2 (±14), 74.7 (65.9–81.4)] met the inclusion criteria of sparse early ischaemic signs on initial standard cranial computed tomography (CT) (ASPECT score ≥7), large vessel occlusion in the anterior circulation on CT angiography and start of treatment within 6 h of onset of symptoms. After consensual interdisciplinary treatment decisions 130 patients (4.2%) received IA treatment – in the majority stent‐assisted thrombectomy in combination with intravenous (IV) recombinant tissue plasminogen activator – and 24 patients (0.7%) standard IV thrombolysis. On 3 months' follow‐up an overall significant improvement of disability ( P = 0.05) as measured by the modified Rankin Scale was shown in favour of the IA treatment group. Good functional outcome was achieved in about twice as many patients (IA vs. IV, 41.2% vs. 21.2%; P = 0.078). Conclusion: By choosing pragmatic inclusion criteria state‐of‐the‐art IA therapy of a specialized tertiary stroke centre can be safely applied under real‐world conditions to a higher percentage of patients with similar success to the recently published RCTs.